Post-transfusion purpura: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
m (Template)
 
Line 6: Line 6:
'''Post-transfusion purpura''' ('''PTP''') is an adverse reaction to a [[blood transfusion]] or [[platelet transfusion]] that occurs when the body produces [[alloantibodies]] to the introduced [[blood platelet|platelets']] [[antigens]]. These alloantibodies destroy the patient's platelets leading to [[thrombocytopenia]], a rapid decline in platelet count.<ref>{{Citation|author=Washington University School of Medicine; Cooper, Daniel E.; J Krainik, Andrew; J Lubner, Sam; EL Reno, Hilary | authorlink= | title=The Washington Manual of Medical Therapeutics (Spiral Manual Series) | publisher=Lippincott Williams  Wilkins | location= | isbn=978-0-7817-8125-1 | page=519}}</ref> PTP usually presents 5–12 days after transfusion, and is a potentially fatal condition.
'''Post-transfusion purpura''' ('''PTP''') is an adverse reaction to a [[blood transfusion]] or [[platelet transfusion]] that occurs when the body produces [[alloantibodies]] to the introduced [[blood platelet|platelets']] [[antigens]]. These alloantibodies destroy the patient's platelets leading to [[thrombocytopenia]], a rapid decline in platelet count.<ref>{{Citation|author=Washington University School of Medicine; Cooper, Daniel E.; J Krainik, Andrew; J Lubner, Sam; EL Reno, Hilary | authorlink= | title=The Washington Manual of Medical Therapeutics (Spiral Manual Series) | publisher=Lippincott Williams  Wilkins | location= | isbn=978-0-7817-8125-1 | page=519}}</ref> PTP usually presents 5–12 days after transfusion, and is a potentially fatal condition.


==Mechanism and treatment==
==Historical Perspective==
 
==Classification==
 
==Pathophysiology==
PTP is rare, but usually occurs in women who have had multiple pregnancies or in people who have undergone previous transfusions.  The precise mechanism leading to PTP is unknown, but it most commonly occurs in individuals whose platelets lack the [[HPA-1a]] antigen (old name: PL<sup>A1</sup>).  The patient develops antibodies to the HPA-1a antigen leading to platelet destruction. In some cases, HPA-5b has also been implicated. It is unclear why alloantibodies attack the patient's own, as well as the introduced platelets. Probable explanation for this is that the recipient's platelet acquire the phenotype of donor's platelet by binding of the soluble antigens from the donor onto the recipient's platelet.<ref>{{citation
PTP is rare, but usually occurs in women who have had multiple pregnancies or in people who have undergone previous transfusions.  The precise mechanism leading to PTP is unknown, but it most commonly occurs in individuals whose platelets lack the [[HPA-1a]] antigen (old name: PL<sup>A1</sup>).  The patient develops antibodies to the HPA-1a antigen leading to platelet destruction. In some cases, HPA-5b has also been implicated. It is unclear why alloantibodies attack the patient's own, as well as the introduced platelets. Probable explanation for this is that the recipient's platelet acquire the phenotype of donor's platelet by binding of the soluble antigens from the donor onto the recipient's platelet.<ref>{{citation
  | last = Gresele
  | last = Gresele
Line 23: Line 27:
  | isbn = 0-521-80261-X
  | isbn = 0-521-80261-X
}}
}}
</ref> It is usually self-limiting, but [[IVIG]] therapy is the primary treatment.<ref>{{citation
</ref>
==Causes==
 
==Differentiating {{PAGENAME}} from Other Diseases==
 
==Epidemiology and Demographics==
 
==Risk Factors==
 
==Screening==
 
==Natural History, Complications, and Prognosis==
===Natural History===
 
===Complications===
 
===Prognosis===
 
==Diagnosis==
===Diagnostic Criteria===
 
===History and Symptoms===
 
===Physical Examination===
 
===Laboratory Findings===
 
===Imaging Findings===
 
===Other Diagnostic Studies===
 
==Treatment==
===Medical Therapy===
It is usually self-limiting, but [[IVIG]] therapy is the primary treatment.<ref>{{citation
  | last = Hillyer
  | last = Hillyer
  | first = Christopher D.
  | first = Christopher D.
Line 42: Line 79:
}}
}}
</ref> [[Plasmapheresis]] is also an option for treatment.<ref>{{cite book |last= Hoffbrand |first= A. V. |author2=P.A.H. Moss |author3=J.E. Pettit |title= [[Essential Haematology: 5th Edition]] |publisher= [[Blackwell Publishing]] |year= 2006 |isbn= 1-4051-3649-9}}</ref>
</ref> [[Plasmapheresis]] is also an option for treatment.<ref>{{cite book |last= Hoffbrand |first= A. V. |author2=P.A.H. Moss |author3=J.E. Pettit |title= [[Essential Haematology: 5th Edition]] |publisher= [[Blackwell Publishing]] |year= 2006 |isbn= 1-4051-3649-9}}</ref>
===Surgery===


===Prevention===
==See also==
==See also==
* [[Blood transfusion]]
* [[Blood transfusion]]
Line 50: Line 90:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Transfusion medicine]]
[[Category:Hematology]]

Latest revision as of 20:59, 23 June 2016

WikiDoc Resources for Post-transfusion purpura

Articles

Most recent articles on Post-transfusion purpura

Most cited articles on Post-transfusion purpura

Review articles on Post-transfusion purpura

Articles on Post-transfusion purpura in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Post-transfusion purpura

Images of Post-transfusion purpura

Photos of Post-transfusion purpura

Podcasts & MP3s on Post-transfusion purpura

Videos on Post-transfusion purpura

Evidence Based Medicine

Cochrane Collaboration on Post-transfusion purpura

Bandolier on Post-transfusion purpura

TRIP on Post-transfusion purpura

Clinical Trials

Ongoing Trials on Post-transfusion purpura at Clinical Trials.gov

Trial results on Post-transfusion purpura

Clinical Trials on Post-transfusion purpura at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Post-transfusion purpura

NICE Guidance on Post-transfusion purpura

NHS PRODIGY Guidance

FDA on Post-transfusion purpura

CDC on Post-transfusion purpura

Books

Books on Post-transfusion purpura

News

Post-transfusion purpura in the news

Be alerted to news on Post-transfusion purpura

News trends on Post-transfusion purpura

Commentary

Blogs on Post-transfusion purpura

Definitions

Definitions of Post-transfusion purpura

Patient Resources / Community

Patient resources on Post-transfusion purpura

Discussion groups on Post-transfusion purpura

Patient Handouts on Post-transfusion purpura

Directions to Hospitals Treating Post-transfusion purpura

Risk calculators and risk factors for Post-transfusion purpura

Healthcare Provider Resources

Symptoms of Post-transfusion purpura

Causes & Risk Factors for Post-transfusion purpura

Diagnostic studies for Post-transfusion purpura

Treatment of Post-transfusion purpura

Continuing Medical Education (CME)

CME Programs on Post-transfusion purpura

International

Post-transfusion purpura en Espanol

Post-transfusion purpura en Francais

Business

Post-transfusion purpura in the Marketplace

Patents on Post-transfusion purpura

Experimental / Informatics

List of terms related to Post-transfusion purpura

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Post-transfusion purpura (PTP) is an adverse reaction to a blood transfusion or platelet transfusion that occurs when the body produces alloantibodies to the introduced platelets' antigens. These alloantibodies destroy the patient's platelets leading to thrombocytopenia, a rapid decline in platelet count.[1] PTP usually presents 5–12 days after transfusion, and is a potentially fatal condition.

Historical Perspective

Classification

Pathophysiology

PTP is rare, but usually occurs in women who have had multiple pregnancies or in people who have undergone previous transfusions. The precise mechanism leading to PTP is unknown, but it most commonly occurs in individuals whose platelets lack the HPA-1a antigen (old name: PLA1). The patient develops antibodies to the HPA-1a antigen leading to platelet destruction. In some cases, HPA-5b has also been implicated. It is unclear why alloantibodies attack the patient's own, as well as the introduced platelets. Probable explanation for this is that the recipient's platelet acquire the phenotype of donor's platelet by binding of the soluble antigens from the donor onto the recipient's platelet.[2]

Causes

Differentiating Post-transfusion purpura from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

It is usually self-limiting, but IVIG therapy is the primary treatment.[3] Plasmapheresis is also an option for treatment.[4]

Surgery

Prevention

See also

References

  1. Washington University School of Medicine; Cooper, Daniel E.; J Krainik, Andrew; J Lubner, Sam; EL Reno, Hilary, The Washington Manual of Medical Therapeutics (Spiral Manual Series), Lippincott Williams Wilkins, p. 519, ISBN 978-0-7817-8125-1
  2. Gresele, Paolo; Page, Clive P.; Fuster, Valentin; Vermylen, Jos (2002), Platelets in Thrombotic and Non-thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics (1st ed.), Cambridge University Press, p. 551, ISBN 0-521-80261-X
  3. Hillyer, Christopher D.; Hillyer, Krista; Strobl, Frank; Jefferies, Leigh C.; Silberstein, Leslie E. (2001), Handbook of Transfusion Medicine (1st ed.), Academic Press, p. 328, ISBN 0-12-348775-7
  4. Hoffbrand, A. V.; P.A.H. Moss; J.E. Pettit (2006). Essential Haematology: 5th Edition. Blackwell Publishing. ISBN 1-4051-3649-9.